Columbia Laboratories to Discuss Second Quarter 2006
Financial Results on August 9, 2006 Conference Call
LIVINGSTON, NJ – July 31, 2006 - Columbia Laboratories, Inc. (NASDAQ: CBRX) will hold a conference call on August 9, 2006 to review and discuss financial results of the second quarter and six months ended June 30, 2006. Robert Mills, Columbia’s president and chief executive officer, and David Weinberg, chief financial officer, will host the call.
Access information
| Date: | Wednesday, August 9, 2006 |
| Time: | 11:00 AM ET |
| U.S./Canada dial-in number: | (866) 558-6338 |
| International dial-in number: | (702) 477-7800 |
| Participant passcode: | 3151 |
| Live webcast: | www.columbialabs.com under "Events" in the Investor section |
Replay Access Information A recording of the conference call will be available two hours after completion until August 14, 2006 at 11:59 PM ET at (866) 800-3850 (U.S.) and (808) 237-2390 (International). The replay password is 3085. The webcast will be archived for on-demand listening for one year on Columbia Laboratories’ website, www.columbialabs.com, under "Events" in the Investor section.
About Columbia Laboratories, Inc.
Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of women's health care and endocrinology products. Columbia markets Prochieve® 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency, and Prochieve® 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets Striant® (testosterone buccal system) for the treatment of hypogonadism in men. Columbia's products and product candidates utilize the Company's bioadhesive drug delivery technology, which is able to deliver a broad range of compounds, including peptides, across many of the body’s mucosal surfaces to address numerous therapeutic areas. The Company is investigating the potential utility of Prochieve® 8% in the prevention of preterm delivery and developing a vaginally-administered lidocaine product to prevent and treat dysmenorrhea and pelvic pain. For more information, please visit www.columbialabs.com.
Striant® and Prochieve® are registered trademarks of Columbia Laboratories, Inc.
###